Nuevolution, a Danish small molecule lead discovery company, says Ton Berkien will join the company on 1 January 2014 as Chief Business Officer. He will lead the Copenhagen-based firm's commercial and business development efforts and as a member of the Executive Management team, will play a key part in strategy planning going forward.
Berkien was most recently acting Head of Corporate Development/M&A at Takeda Pharmaceuticals International, Switzerland. Prior to Takeda, he held a similar position at Nycomed Pharmaceuticals.
From 2003–2007, Berkien was Director of Competitive Intelligence at Ferring Pharmaceuticals, where he was responsible for CI project management in both the R&D and commercial organisation. Earlier, he held Senior Manager positions at PricewaterhouseCoopers, Rijnconsult, KPMG and Gilde Investment Management.
